Evofem Biosciences Inc (EVFM)

Evofem Biosciences Stock Price & Analysis


EVFM Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.06 - $8.10
Previous Close$0.07
Average Volume (3M)2.23M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$19.89M
Total Debt (Recent Filing)$125.74M
Price to Earnings (P/E)>-0.1
Next EarningsMar 02, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-19.55
Shares Outstanding85,459,214
Standard Deviation0.42
10 Day Avg. Volume1,704,633
30 Day Avg. Volume2,229,838
Price to Book (P/B)-0.03
Price to Sales (P/S)0.58
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside698.19% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering2


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Evofem Biosciences’s price range in the past 12 months?
Evofem Biosciences lowest stock price was $0.06 and its highest was $8.10 in the past 12 months.
    What is Evofem Biosciences’s market cap?
    Currently, no data Available
    When is Evofem Biosciences’s upcoming earnings report date?
    Evofem Biosciences’s upcoming earnings report date is Mar 02, 2023 which is in 85 days.
      How were Evofem Biosciences’s earnings last quarter?
      Evofem Biosciences released its earnings results on Nov 09, 2022. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.04.
        Is Evofem Biosciences overvalued?
        According to Wall Street analysts Evofem Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Evofem Biosciences pay dividends?
          Evofem Biosciences does not currently pay dividends.
          What is Evofem Biosciences’s EPS estimate?
          Evofem Biosciences’s EPS estimate is -$0.21.
            How many shares outstanding does Evofem Biosciences have?
            Evofem Biosciences has 93,508,415 shares outstanding.
              What happened to Evofem Biosciences’s price movement after its last earnings report?
              Evofem Biosciences reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Evofem Biosciences?
                Among the largest hedge funds holding Evofem Biosciences’s share is Soros Fund Mangment LLC. It holds Evofem Biosciences’s shares valued at N/A.


                  Evofem Biosciences Stock Smart Score

                  Not Ranked
                  This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Evofem Biosciences Inc

                  Evofem Biosciences, Inc. develops therapeutic solutions to meet sexual and reproductive health needs of women. Its product include Amphora Contraceptive for the prevention of pregnancy, antimicrobial drug product for the prevention of sexually transmitted infections and Antimicrobial Drug product to prevent the reoccurrence of bacterial vaginosis. The company was founded in 2007 and is headquartered in San Diego, CA.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Artelo Biosciences
                  Adial Pharmaceuticals
                  Protect Pharmaceutical
                  CNS Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis